 |
|
Discovery of Tuberculosis Bacterium Enzyme Paves Way for New TB Drugs
March 30, 2009A team of University of Maryland scientists has paved the way for the development of new drug therapies to combat active and asymptomatic (latent) tuberculosis infections by characterizing the unique structure and mechanism of an enzyme in M. tuberculosis, the bacterium that causes the disease. Assistant Professor of Chemistry and Biochemistry Barbara Gerratana, in the university's College of Chemical and Life Sciences, led the research team, which included her graduate student Melissa Resto and Assistant Professor Nicole LaRonde-LeBlanc.
"The NAD+ synthetase enzyme that our study describes is absolutely essential for the survival of the tuberculosis bacteria and an important drug target. We can now use the information we have about its structure and mechanism to develop inhibitors for this enzyme," Gerratana explained.
The study, titled "Regulation of active site coupling in glutamine-dependent NAD+ synthetase," was published in on March 8, 2009 in Nature Structural & Molecular Biology.
The development of new drugs to combat tuberculosis (TB) has become urgent, as strains of TB resistant to all major anti-TB drugs have emerged worldwide. The World Health Organization estimates that one third of the world's population is asymptomatically infected with TB and that ten percent will eventually develop the disease.
According to other leading TB researchers, these new findings from Gerratana and her colleagues will be extremely valuable for the design of structure-based inhibitors specific for M. tuberculosis NAD+ synthetase and may lead to the development of new drugs to combat and eliminate the disease.
"NadE [NAD+ synthetase] represents one of a small handful of TB drug targets that has iron-clad validation, the lack of a crystal structure was the only serious impediment to drug development and this study represents a hugely important step forward" said Clifton E. Barry, Chief of the Tuberculosis Research Section of the Intramural Research Division of the National Institute of Allergy and Infectious Diseases. "Inhibiting NadE even kills non-replicating cells, so this discovery may well benefit the one-third of the human population that carries latent bacteria."
NAD+ synthetase is responsible for making NAD+, a coenzyme found in all living cells that is involved in regulating many cellular processes and in reduction-oxidation metabolic reactions. More than one biosynthetic pathway is usually involved in NAD+ production. In humans, NAD+ can be obtained through several different complex pathways, and not all of the pathways utilize NAD+ synthetase to produce NAD+. Unlike in humans, however, there are only two pathways involved in producing NAD+ in the tuberculosis bacterium and both depend on the activity of NAD+ synthetase to obtain NAD+.
"We are optimistic about the potential for developing new drugs that will effectively target this enzyme in TB and minimize side effects to humans, since we have NAD+ biosynthetic pathways that are independent of the NAD+ synthetase activity," Gerratana said.
The World Health Organization reports that a new instance of TB infection occurs every second. Current treatment of tuberculosis targets the active tuberculosis bacterium and has little effect on the non-replicating bacterium."If we don't tackle latent tuberculosis, this disease will not be eradicated," Gerratana said.
Regulation of active site coupling in glutamine-dependent NAD+ synthetase was written by Nicole LaRonde-LeBlanc, Melissa Resto, and Barbara Gerratana. This work was supported by a PRF grant from the American Chemical Society to B.G. and by start-up funds to B.G. and N.L.L. from the Dept. of Chemistry and Biochemistry, University of Maryland , College Park .
University of Maryland
The development of new drugs to combat tuberculosis (TB) has become urgent, as strains of TB resistant to all major anti-TB drugs have emerged worldwide. The World Health Organization estimates that one third of the world's population is asymptomatically infected with TB and that ten percent will eventually develop the disease.
According to other leading TB researchers, these new findings from Gerratana and her colleagues will be extremely valuable for the design of structure-based inhibitors specific for M. tuberculosis NAD+ synthetase and may lead to the development of new drugs to combat and eliminate the disease.
"NadE [NAD+ synthetase] represents one of a small handful of TB drug targets that has iron-clad validation, the lack of a crystal structure was the only serious impediment to drug development and this study represents a hugely important step forward" said Clifton E. Barry, Chief of the Tuberculosis Research Section of the Intramural Research Division of the National Institute of Allergy and Infectious Diseases. "Inhibiting NadE even kills non-replicating cells, so this discovery may well benefit the one-third of the human population that carries latent bacteria."
NAD+ synthetase is responsible for making NAD+, a coenzyme found in all living cells that is involved in regulating many cellular processes and in reduction-oxidation metabolic reactions. More than one biosynthetic pathway is usually involved in NAD+ production. In humans, NAD+ can be obtained through several different complex pathways, and not all of the pathways utilize NAD+ synthetase to produce NAD+. Unlike in humans, however, there are only two pathways involved in producing NAD+ in the tuberculosis bacterium and both depend on the activity of NAD+ synthetase to obtain NAD+.
"We are optimistic about the potential for developing new drugs that will effectively target this enzyme in TB and minimize side effects to humans, since we have NAD+ biosynthetic pathways that are independent of the NAD+ synthetase activity," Gerratana said.
The World Health Organization reports that a new instance of TB infection occurs every second. Current treatment of tuberculosis targets the active tuberculosis bacterium and has little effect on the non-replicating bacterium."If we don't tackle latent tuberculosis, this disease will not be eradicated," Gerratana said.
Regulation of active site coupling in glutamine-dependent NAD+ synthetase was written by Nicole LaRonde-LeBlanc, Melissa Resto, and Barbara Gerratana. This work was supported by a PRF grant from the American Chemical Society to B.G. and by start-up funds to B.G. and N.L.L. from the Dept. of Chemistry and Biochemistry, University of Maryland , College Park .
University of Maryland
Tuberculosis Current Events and Tuberculosis News RSSStudy reveals why certain drug combinations backfire
Combination drug therapy has become a staple for treating many infections. For instance, doctors treat extensively drug resistant forms of tuberculosis with one drug that breaks down the pathogen's protective barriers and opens the door for another to deliver the deathblow.
Drug industry, nonprofits join forces to fight world's neglected diseases
Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year.
U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat
Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.
1930s drug slows tumor growth
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease.
There's a speed limit to the pace of evolution, Penn biologists say
Researchers at the University of Pennsylvania have developed a theoretical model that informs the understanding of evolution and determines how quickly an organism will evolve using a catalogue of "evolutionary speed limits."
Cell phones become handheld tools for global development
Mobile phones are on the verge of becoming powerful tools to collect data on many issues, ranging from global health to the environment.
Will genomics help prevent the next pandemic?
This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease.
Exon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice
An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan.
Scientists take step toward simple and portable tuberculosis tests for developing world
Two billion people worldwide carry the pathogen that causes tuberculosis (TB), and most of them do not even know they are infected. This is because some 90 percent of people with TB have "latent" infections. They have no symptoms, they can't spread the disease to others and the bug remains dormant in their lungs -- often for years.
High mortality rates may explain small body size
A new study suggests that high mortality rates in small-bodied people, commonly known as pygmies, may be part of the reason for their small stature.
More Tuberculosis Current Events and Tuberculosis News Articles
 |
The White Plague: Tuberculosis, Man and Society by Jean Dubos (Author) |
 |
Tuberculosis: A Comprehensive Clinical Reference by H. Simon Schaaf MBChB(Stellenbosch) MMed Paed(Stellenbosch) DCM(Stellenbosch) MD Paed(Stellenbosch) (Editor), Alimuddin I. Zumla BSc MBChB MSc PhD(Lond) FRCP(Lond) FRCP(Edin) (Editor) This book provides all the vital information you need to know about tuberculosis, especially in the face of drug-resistant strains of the disease. Coverage includes which patient populations face an elevated risk of infection, as well as which therapies are appropriate and how to correctly monitor ongoing treatment so that patients are cured. Properly administer screening tests, interpret their results, and identify manifestations of the disease, with authoritative guidance from expert clinicians from around the world. Discusses screening tests for tuberculosis so you can interpret their results and identify not only common manifestations of the disease, but also those that are comparatively rare-such as tuberculosis in pregnant women. Covers all clinical aspects of tuberculosis... |
 |
The Forgotten Plague: How the Battle Against Tuberculosis Was Won - And Lost by Frank Ryan (Author) Tuberculosis has claimed more than a billion lives worldwide. In this acclaimed book, Dr. Frank Ryan tells the remarkable story of the dedicated doctors, chemists, and bacteriologists who halted the course of this ferocious disease--until the "old enemy" found in AIDS a deadly ally to form a drug-resistant synergy. 8 pages of photos. |
 |
Tuberculosis (TUBERCULOSIS ( ROM)) by William N Rom (Editor), Stuart M Garay (Editor) New York Univ., NY. Summarizes the current advances in tuberculosis and discusses the pathology and pathogenesis of the disease. Also covers complications and treatment options. Chapters include history and epidemiology, genomics and microbiology, host response, therapy, and prevention and control. Previous edition: c1996. DNLM: Tuberculosis--Pulmonary. |
 |
Captain of Death: The Story of Tuberculosis by Thomas M. Daniel (Author) The dramatic story of tuberculosis is told here in a straightforward and accessible style. It presents the stories of persons connected with the disease, either as victims, or as those who made contributions to our knowledge of it; in addition to these personal accounts, the book unfolds the history and explains the pathogenesis of TB. The re-emergence of tuberculosis as a major American public health hazard has focused much attention on this ancient disease. This book offers a comprehensive account of the disease from prehistoric times through to the present day, detailing the attempts to eradicate it completely. Its four separate sections (the spread of tuberculosis; its infectious nature; susceptibility to it; and methods of treatment) are linked through the device of presenting... |
 |
The Bioarchaeology of Tuberculosis: A Global View on a Reemerging Disease by CHARLOTTE ROBERTS (Author), JANE BUIKSTRA (Author) Though apparently in decline during the first half of the 20th century, tuberculosis has reawakened in both developed and developing countries, particularly among susceptible populations with immunodeficiency disorders. |
 |
Handbook of Tuberculosis by Stefan H. E. Kaufmann (Editor), Paul van Helden (Editor), Eric Rubin (Editor), Warwick J. Britton (Editor) Tuberculosis (TB), a deadly airborne disease caused by the bacterium Mycobacterium tuberculosis, takes the lives of almost 2 million people each year and is considered to be the most common infectious disease in the world. However, thanks to the efforts of researchers such as the volumes’ lead editor, Dr. Stefan H. E. Kaufmann, there have been several recent advances in fighting the disease. Dr. Stefan Kaufmann, the Founding Director of the Max Planck Institute for Infection Biology in Berlin and Professor of Microbiology and Immunology at the Charité at the Humboldt University, Berlin, has published more than 600 scientific articles and currently serves as President of the European Federation of Immunological Societies and Chair of the Immunology Division of the American... |
 |
The Return of the White Plague: Global Poverty and the 'New' Tuberculosis by Matthew Gandy (Editor), Alimuddin Zumla (Editor) The dramatic increase since the 1980s in the global prevalence of tuberculosis, a disease destined as recently as thirty years ago for complete eradication, is a story of medical failure. A pandemic whose geography defies simple categorization—it ranges from schools in the UK to prisons in Russia, from refugee camps in central Africa to affluent suburbs in North America—the 'new' tuberculosis is derived from a combination of different developments such as collapsing health-care services, shifting patterns of poverty and inequality, the spread of HIV, and the emergence of virulent drug-resistant strains. This collection provides an international survey of current thought on the spread and control of tuberculosis, covering historical, social, political, and medical aspects. While... |
 |
Historic Tuberculosis Films DVD: History of Pulmonary & Mycobacterium TB & Lung Disease Films Table of Contents: Tuberculosis (1955)11 minutes - This is a fun little film that shows a general history and overview of the effects of tuberculosis on our society. / On the Firing Line (1936) 20 minutes - A fantastic film that has great timeless statistics as well as footage and information about the fight against tuberculosis by the National Tuberculosis Association. / You are the Switchman (1951) 12 minutes running time - A film about noticing the warning signs of cancer and taking appropriate preventative action. You Are the Switchman was a groundbreaking video because it was released two years before the link between smoking cigarettes and cancer was officially out in the open. / City of Hope (1930s) 16 minutes - The Los Angeles Tuberculosis Sanatorium produced this film in the... |
 |
Living in the Shadow of Death: Tuberculosis and the Social Experience of Illness in American History by Sheila M. Rothman (Author) For more than 150 years, until well into the twentieth century, tuberculosis was the dreaded scourge that AIDS is for us today. Based on the diaries and letters of hundreds of individuals over five generations, Living in the Shadow of Death is the first book to present an intimate and evocative portrait of what it was like for patients as well as families and communities to struggle against this dreaded disease. "Consumption", as it used to be called, is one of the oldest known diseases. But it wasn't until the beginning of the nineteenth century that it became pervasive and feared in the United States, the cause of one out of every five deaths. Consumption crossed all boundaries of geography and social class. How did people afflicted with the disease deal with their fate? How did their... |
| © 2009 BrightSurf.com |